Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure

American Journal of Cardiology

Volumn 80, Issue 11, 1997, Pages 1453-1458

  Grossman, Ehud ^a   Messerli, Franz H ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b OCHSNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; NORADRENALIN;

ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE MONITORING; DATA ANALYSIS; DIAGNOSTIC VALUE; DRUG EFFICACY; HEART RATE; HUMAN; HYPERTENSION; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL;

ADULT; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; DIHYDROPYRIDINES; DILTIAZEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; FOLLOW-UP STUDIES; HEART RATE; HUMANS; HYPERTENSION; MEDLINE; MIDDLE AGED; NOREPINEPHRINE; RETROSPECTIVE STUDIES; TIME FACTORS; VERAPAMIL;

EID: 0030807893     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00722-4     Document Type: Article

References (76)

1. Chobanian AV. Calcium channel blockers. Lessons learned from MIDAS and other clinical trials [editorial]. JAMA. 276:1996;829-830.
2. Beevers DG, Sleight P. Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension is there a risk? Br Med J. 312:1996;1143-1145.
3. Julius S, Jamerson K. Sympathetics, insulin resistance and coronary risk in hypertension the "chicken-and-egg"question [editorial] . J Hypertens. 12:1994;495-502.
4. Julius S. Corcoran lecture. Sympathetic hyperactivity and coronary risk in hypertension. Hypertension. 21:1993;886-893.
5. Julius S, Gudbrandsson T, Jamerson K, Tariq Shahab S Andersson O. The hemodynamic link between insulin resistance and hypertension. J Hypertens. 9:1991;983-986.
6. Deibert DC, DeFronzo RA. Epinephrine-induced insulin resistance in man. J Clin Invest. 65:1980;717-721.
7. Ruzicka M, Leenen FHH. Relevance of 24 H blood pressure profile and sympathetic activity for outcome on short- versus long-acting 1,4-dihydropyridines. Am J Hypertens. 6:1996;86-94.
8. Barron HV, Lesh MD. Autonomic nervous system and sudden cardiac death. J Am Coll Cardiol. 27:1996;1053-1060.
9. Ardlie NG, Glew G, Schwartz CJ. Influence of catecholamines on nucleotide-induced platelet aggregation. Nature. 212:1966;415-417.
10. O'Brien JR. Some effects of adrenaline and anti-adrenaline compounds on platelets in vitro and in vivo. Nature. 200:1963;763-764.
11. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 311:1984;819-823.
12. Cohn JN. Sympathetic nervous system activity and the heart. Am J Hypertens. 2:(12 pt 2):1989;353S-356S.
13. Rea RF, Eckberg DL, Fritsch JM, Goldstein DS. Relation of plasma norepinephrine and sympathetic traffic during hypotension in humans. Am J Physiol. 258:(4 pt 2):1990;R982-R986.
14. Agabiti-Rosei E, Muiesan ML, Romanelli G, Castellano M, Beschi M, Corea L, Muiesan G. Similarities and differences in the antihypertensive effect of two calcium antagonist drugs, verapamil and nifedipine. J Am Coll Cardiol. 7:1986;916-924.
15. Schmieder RE, Messerli FH, Garavaglia GE, Nunez BD. Cardiovascular effects of verapamil in patients with essential hypertension. Circulation. 75:1987;1030-1036.
16. Kailasam MT, Parmer RJ, Cervenka JH, Wu RA, Ziegler MG, Kennedy BP, Adegbile IA, O'Connor DT. Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. Hypertension. 26:1995;143-149.
17. Amodeo C, Kobrin I, Ventura HO, Messerli FH, Frohlich ED. Immediate and short-term hemodynamic effects of diltiazem in patients with hypertension. Circulation. 73:1986;108-113.
18. Laederach K, Weidmann P, Lauener F, Gerber A, Ziegler WH. Comparative acute effects of the calcium channel blockers tiapamil, nisoldipine, and nifedipine on blood pressure and some regulatory factors in normal and hypertensive subjects. J Cardiovasc Pharmacol. 8:1986;294-302.
19. Corea L, Miele N, Bentivoglio M, Boschetti E, Agabiti-Rosei E, Muiesan G. Acute and chronic effects of nifedipine on plasma renin activity and plasma adrenaline and noradrenaline in controls and hypertensive patients. Clin Sci. 57:(suppl 5):1979;115-117.
20. Kiowski W, Bertel O, Erne P, Bolli P, Hulthën L, Ritz R, Bühler FR. Hemodynamic and reflex responses to acute and chronic antihypertensive therapy with the calcium entry blocker nifedipine. Hypertension. 5:(2 pt 2):1983;I70-I74.
21. Lederballe Pedersen O Mikkelsen E, Kornerup HJ, Christensen NJ. Effects of nifedipine on blood pressure, regional hemodynamics, plasma renin activity and plasma catecholamines in patients with arterial hypertension. Acta Med Scand Suppl. 625:1979;65-67.
22. Kusano E, Asano Y, Takeda K, Matsumoto Y, Ebihara A, Hosoda S. Hypotensive effect of nifedipine in hypertensive patients with chronic renal failure. Arzneimittelforschung. 32:1982;1575-1580.
23. Lehmann M, Durr H, Arratibel-Imaz I, Balle C, Keller E, Merkelbach H, Keul J. Plasma catecholamine and cardiovascular responses to nifedipine in hypertensives WHO-stage II. Arzneimittelforschung. 39:1989;1593-1596.
24. Kiowski W, Erne P, Bertel O, Bolli P, Buhler F. Acute and chronic sympathetic reflex activation and antihypertensive response to nifedipine. J Am Coll Cardiol. 7:1986;344-348.
25. Murphy MB, Scriven AJ, Brown MJ, Causon R, Dollery CT. The effects of nifedipine and hydralazine induced hypotension on sympathetic activity. Eur J Clin Pharmacol. 23:1982;479-482.
26. Savonitto S, Bevilacqua M, Chebat E, Vago T, Bertora P, Baldi G, Renesto E, Peruzzi E, Sardina M, Norbiato G. Beta-adrenergic receptors and reflex tachycardia after single and repeated felodipine administration in essential hypertension. J Cardiovasc Pharmacol. 17:1991;970-975.
27. Katzman PL, Hulthen UL, Hokfelt B. Effects of the calcium antagonist felodipine on the sympathetic and renin-angiotensin-aldosterone systems in essential hypertension. Acta Med Scand. 223:1988;125-131.
28. Lindqvist M, Kahan T, Melcher A, Hjemdahl P. Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension. Hypertension. 24:1994;287-296.
29. Katzman PL, Hulthen UL, Hokfelt B. Catecholamines, renin-angiotensin-aldosterone, and cardiovascular response during exercise following acute and long-term calcium antagonism with felodipine in essential hypertension. J Cardiovasc Pharmacol. 10:1987;439-444.
30. Hedner T, Samuelsson O, Sjogren E, Elmfeldt D. Treatment of essential hypertension with felodipine in combination with a diuretic. Eur J Clin Pharmacol. 30:1986;133-139.
31. Leenen FH, Holliwell DL. Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. Am J Cardiol. 69:1992;639-645.
32. Katzman PL. Calcium antagonism with felodipine in essential hypertension. Effects on cardiovascular and renal function, the sympathetic and the renin-angiotensin-aldosterone systems, glucose tolerance and glucoregulatory hormones. Acta Med Scand Suppl. 720:1987;1-62.
33. Thananopavarn C Golub MS, Eggena P, Barrett JD, Sambhi MP. Renal effects of nitrendipine monotherapy in essential hypertension. J Cardiovasc Pharmacol. 6 Suppl 7:1984;S1032-S1036.
34. Ventura HO Messerli FH, Oigman W, Dunn FG, Reisin E, Frohlich ED. Immediate hemodynamic effects of a new calcium-channel blocking agent (nitrendipine) in essential hypertension. Am J Cardiol. 51:1983;783-786.
35. Mancia G Parati G, Grassi G, Pomidossi G, Giannattasio C, Casadei R, Groppelli A, Saino A, Gregorini L, Perondi R, Zanchetti A. Calcium antagonists and neural control of circulation in essential hypertension. J Hypertens Suppl. 5:1987;S49-S55.
36. Frohlich ED McLoughlin M, Ketelhut R. Hemodynamic and metabolic effects of intravenous clentiazem in hypertensive patients. Am J Cardiol. 69:1992;229-232.
37. Conrad KA Fagan TC, Mayshar P, Davis TP, Johnson DG. Antihypertensive effects of parenteral nicardipine alone and in combination with captopril. Clin Pharmacol Ther. 42:1987;113-118.
38. Ryman KS Kubo SH, Shaknovich A, Cody RJ. Influence of baseline hemodynamic status and sympathetic activity on the response to nicardipine, a new dihydropyridine, in patients with hypertension or chronic congestive heart failure. Clin Pharmacol Ther. 41:1987;483-489.
39. Schwietzer G Distler A, Reeck S, Thiede HM, Philipp T. Hypotensive action of calcium antagonists as related to plasma noradrenaline and reactivity to noradrenaline. J Hypertens Suppl. 1:1983;102-104.
40. Mohanty PK Sowers JR, McNamara C, Welch B, Beck F, Thames M. Effects of diltiazem on hormonal and hemodynamic responses to lower body negative pressure and tilt in patients with mild to moderate systemic hypertension. Am J Cardiol. 56:1985;28H-33H.
41. Mohanty PK, Sowers JR, Thames MD. Effects of hydrochlorothiazide and diltiazem on reflex vasoconstriction in hypertension. Hypertension. 10:1987;35-42.
42. Schulte KL Meyer, -Sabellek WA Haertenberger A, Thiede HM, Roecker L, Distler A, Gotzen R. Antihypertensive and metabolic effects of diltiazem and nifedipine. Hypertension. 8:1986;859-865.
43. Klein W Brandt D, Vrecko K, Harringer M. Role of calcium antagonists in the treatment of essential hypertension. Circ Res. 52:(2 pt 2):1983;I174-I181.
44. Inouye IK Massie BM, Benowitz N, Simpson P, Loge D. Antihypertensive therapy with diltiazem and comparison with hydrochlorothiazide. Am J Cardiol. 53:1984;1588-1592.
45. Bruun NE, Ibsen H, Nielsen F, Nielsen MD, Moelbak AG, Hartling OJ. Lack of effect of nifedipine on counterregulatory mechanisms in essential hypertension. Hypertension. 8:1986;655-661.
46. Borow KM Neumann A, Lang RM, Ehler D, Valentine-Bates B, Wolff A, Friday K, Murphy M. Noninvasive assessment of the direct action of oral nifedipine and nicardipine on left ventricular contractile state in patients with systemic hypertension: importance of reflex sympathetic responses. J Am Coll Cardiol. 21:1993;939-949.
47. Michel MC Mindermann G, Daul A, Brodde OE. Effects of antihypertensive therapy on human alpha- and beta-adrenoceptors. J Hypertens. 9:1991;601-606.
48. Leenen FH Burns RJ, Myers MG, Frankel D. Effects of nifedipine versus hydralazine on sympathetic activity and cardiac function in patients with hypertension persisting on diuretic plus beta-blocker therapy. Cardiovasc Drugs Ther. 4:1990;499-504.
49. Lee DD Rigonan K, Dequattro V. Increased blood pressure and neural tone in the silent ischemia of hypertension: disparate effects of immediate release nifedipine. J Am Coll Cardiol. 22:1993;1438-1445.
50. Gavras I Gavras H. Nifedipine in the treatment of essential hypertension. J Clin Pharmacol. 25:1985;429-432.
51. Frohlich ED McLoughlin MJ, Losem CJ, Ketelhut R, Messerli FH. Hemodynamic comparison of two nifedipine formulations in patients with essential hypertension. Am J Cardiol. 68:1991;1346-1350.
52. Bruun NE Ibsen H, Nielsen F, Nielsen MD, Molbak AG, Hartling OJ. The influence of nifedipine treatment on counter-regulatory mechanisms in essential hypertension. J Hypertens Suppl. 3:1985;S223-S225.
53. de Vries RJ Quere M, Lok DJ, Sijbring P, Bucx JJ, van Veldhuisen DJ, Dunselman PH. Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of felodipine and enalapril in patients with congestive heart failure. Am J Cardiol. 76:1995;1253-1258.
54. Sudhir K Jennings GL, Bruce A. Cardiovascular-risk reduction: initial diuretic therapy compared with calcium-antagonist (felodipine) therapy for primary hypertension. Med J Aust. 151:1989;277-279.
55. Giles TD Sander GE, Roffidal LC, Thomas MG, Given MB, Quiroz AC. Comparison of nitrendipine and hydrochlorothiazide for systemic hypertension. Am J Cardiol. 60:1987;103-106.
56. Giles TD Sander GE, Roffidal LE, Mazzu A. Comparison of effects of nitrendipine versus hydrochlorothiazide on left ventricular structure and function and neurohumoral status in systemic hypertension. Am J Cardiol. 65:1990;1265-1268.
57. Muller R Steffen HM, Weller P, Kugel C, Freiheit T, Krone W. Changes in plasma norepinephrine concentration and thrombocyte alpha 2-adrenoceptor density during long-term antihypertensive therapy with nitrendipine and captopril. J Cardiovasc Pharmacol. 24:1994;429-433.
58. Pedrinelli R Fouad FM, Tarazi RC, Bravo EL, Textor SC. Nitrendipine, a calcium entry-blocker. Renal and humoral effects in human arterial hypertension. Arch Intern Med. 146:1986;62-65.
59. Lopez LM Mehta JL, Baz R, Aguila E. Effects of nitrendipine and hydralazine on plasma catecholamines in essential hypertension. Clin Pharmacol Ther. 36:1984;444-450.
60. Faulhaber HD Gruner R, Homuth V, Naumann E, Menz M, Hartrodt W, Schmidt J, Mohnike W. Nitrendipine treatment in so-called therapy-resistant arterial hypertension: effect as monotherapy and in combination with propranolol on blood pressure, heart rate, other hemodynamic parameters, plasma renin activity, and catecholamines. J Cardiovasc Pharmacol. 12:(suppl 4):1988;S146-S148.
61. Grossman E Messerli FH, Oren S, Nunez B, Garavaglia GE. Cardiovascular effects of isradipine in essential hypertension. Am J Cardiol. 68:1991;65-70.
62. Halperin AK Icenogle MV, Kapsner CO, Chick TW, Roehnert J, Murata GH. A comparison of the effects of nifedipine and verapamil on exercise performance in patients with mild to moderate hypertension. Am J Hypertens. 6:1993;1025-1032.
63. Stadler P Leonardi L, Riesen W, Ziegler W, Marone C, Beretta-Piccoli C. Cardiovascular effects of verapamil in essential hypertension. Clin Pharmacol Ther. 42:1987;485-492.
64. Katzman PL Henningsen NC, Fagher B, Thulin T, Hulthén UL. Renal and endocrine effects of long-term converting enzyme inhibition as compared with calcium antagonism in essential hypertension. J Cardiovasc Pharmacol. 15:1990;360-364.
65. Evans RR Davis WR, Wallace JM, DiPette DJ, Holland OB. Humoral factors determining the blood pressure response to converting enzyme inhibition and calcium channel blockade. Am J Hypertens. 3:(8 pt 1):1990;605-610.
66. Leenen FH Fourney A. Comparison of the effects of amlodipine and diltiazem on 24-hour blood pressure, plasma catecholamines, and left ventricular mass. Am J Cardiol. 78:1996;203-207.
67. Phillips RA Ardeljan M, Shimabukuro S, Goldman ME, Garbowit DL, Eison HB, Krakoff LR. Normalization of left ventricular mass and associated changes in neurohormones and atrial natriuretic peptide after 1 year of sustained nifedipine therapy for severe hypertension. J Am Coll Cardiol. 17:1991;1595-1602.
68. Phillips RA Ardeljan M, Shimabukuro S, Goldman ME, Garbowit DL, Eison HB, Krakoff LR. Effects of nifedipine-GITS on left ventricular mass and left ventricular filling. J Cardiovasc Pharmacol. 19:(suppl 2):1992;S28-S34.
69. Koenig W Binner L, Gabrielsen F, Sund M, Rosenthal J, Hombach V. Catecholamines and the renin-angiotensin-aldosterone system during treatment with felodipine ER or hydrochlorothiazide in essential hypertension. J Cardiovasc Pharmacol. 18:1991;349-353.
70. Agabiti-Rosei E Muiesan ML, Rizzoni D, Romanelli G, Beschi M, Castellano M. Regression of cardiovascular structural changes after long-term antihypertensive treatment with the calcium antagonist nitrendipine. J Cardiovasc Pharmacol. 18:(suppl 5):1991;S5-S9.
71. Grossman E Oren S, Garavaglia GE, Messerli FH, Frohlich ED. Systemic and regional hemodynamic and humoral effects of nitrendipine in essential hypertension. Circulation. 78:1988;1394-1400.
72. Lopez LM Thorman AD, Mehta JL. Effects of amlodipine on blood pressure, heart rate, catecholamines, lipids and responses to adrenergic stimulus. Am J Cardiol. 66:1990;1269-1271.
73. Brown MJ Dickerson JE. Alpha-blockade and calcium antagonism: an effective and well-tolerated combination for the treatment of resistant hypertension. J Hypertens. 13:1995;701-707.
74. Harano Y Kageyama A, Hirose J, Asakura Y, Yokota T, Ikebuchi M, Suzuki M, Omae T. Improvement of insulin sensitivity for glucose metabolism with the long-acting Ca-channel blocker amlodipine in essential hypertensive subjects. Metabolism. 44:1995;315-319.
75. Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on nifedipine capsules in hypertensive emergencies and pseudoemergencies. JAMA. 276:1996;1328-1331.
76. Alderman MH, Cohen H, Roqué R, Madhavan S. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet. 349:1997;594-598.